InnovaCare Health Boss Dr Shinto

Touted as one of the authority figures in Healthcare provision, Dr Sinto is a man who seems to have won the hearts and minds of all stakeholders in the health sectors. He has managed to take medical care beyond the preconceived notion that accessing medical aid is an expensive affair. This is a single man’s journey through the career ladder from a simple pulmonologist to the Current position that he holds at Innovacare Health. Dr Shinto is currently the Chief Executive Officer (CEO) and president of InnovaCare. It’s one of the leading managed healthcare providers in the country. This was made possible through the able leadership of Dr Shinto.

Dr Shinto is no stranger in the medical field having got his B.S from the University of California. He acquired his medical degree from the University of New York and received his MBA from the university of Redlands. He did his internship Southern California and also kickstarted his career as a Pulmonologist in Southern California. With over two decades worth of experience in the healthcare sector there is very few people who can boast of such a wonderful track record. His academic intellect and entrepreneurial spirit have seen him occupy some of the most lucrative positions in well known healthcare management firms.

Before being appointed as the CEO of InnovaCare, Dr Shinto was the CEO of Aventa Inc which is a highly regarded healthcare management firm. He also had appointments as Medical Management´s Vice President before a move to Orange County´s Cal Optimal Health Plan as its Chief Medical Officer. Dr Shinto also worked extensively for NAMM California as its Chief Medical Officer. In the course of his work as a healthcare practitioner, Dr Shinto has also written several works on matters clinical medicine. This is only but a few of the Jobs undertaken while in the health industry.

Dr Shinto attributes his success to teamwork and proper communication channels. This enables seamless flow of information and ensures that everyone is accountable for their actions. There is also a team of experienced qualified personnel that ensure there is no second guessing of decisions. Interaction with employees of InnovaCare indicate that Dr Shinto is a well respected gentleman who has his workers best interest at heart. The desire and willingness to serve is what makes Dr Shinto great for the job and his positive attitude has seen the team at InnovaCare excel at service delivery.

What You Don’t Know About Jeanmarie Guenot, President and C.E.O Amphivena Therapeutics

 

Jeanmarie Guenot holds a Ph.D from the University of California and has an MBA from the University of Pennsylvania. She studied physical and medical chemistry majoring in quantum and semi-empirical methods for drug design, protein structure prediction, X-ray & NMR refinement, and molecular dynamics. Dr. Guenot has more than 20 years of experience in the biotechnology and pharmaceutical industry. She has spent all those hours of experience in the public and private sectors with keen interests in corporate & commercial development, venture capital, pharmaceutical R&D, business development as well as project & alliance management.

Jeanmarie is the incumbent head of the leadership team of Amphivena Therapeutics, Inc., which was founded in 2013 to treat hematologic malignancies. She has an expansive portfolio, project, and alliance management experience in ophthalmic diseases, autoimmune diseases, oncology, neurology, and cardiovascular diseases. Before assuming her current position, Dr. Guenot held many other positions including serving as vice president for Corporate & Business Development at PDL Biopharma, being a business advisor for Hoffmann-La Roche, and founding SKS Ocular, which is a start-up that is an incubator of ophthalmic companies.

 

With the wealth of experience to her name, Jeanmarie Guenot’s contribution to Amphivena Therapeutics is irrefutable. Under her leadership, the company has devised a new method in the treatment of acute myeloid leukemia through the development of a Bispecific Tetravalent CD33/CD3 TandAb. Cytotoxic chemotherapy has largely been used in the treatment of the disease but with the new development, immunotherapeutic can be used as an alternative.

Still under the headship of Jeanmarie Guenot and led by MPM capital the company was able to raise 14 million U.S dollars in a Series A Financing in 2013. Another achievement that stands out is the company’s ability to make the first and second milestones in an agreement it signed with Janssen Biotech Incorporation. The accord, which was facilitated by Johnson and Johnson, aimed at selecting a candidate against an undisclosed tumor antigen.

This would later be used in doing further research on the hematological malignancies. Following the accomplishment, Amphivena Therapeutic received an imbursement from Jansen Biotech Incorporation and this opened a window for further research and development.  Read more about what Jeanmarie Guenot is doing in the fight against cancer, through her partnership with Takeda.  Otherwise you can follow Jeanmarie personally on Facebook.